Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | CA4 | P22748 | 4/20 | 0.46 |
| ▸ | CA5A | P35218 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12731192 | 0.93 | TSHR (0.76) | TSHRPTPN1SLC5A2CA12CA1 | |
| SCHEMBL18427873 | 0.92 | TSHR (0.65) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL12509908 | 0.87 | TSHR (0.73) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL5523365 | 0.87 | TSHR (0.73) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL5271015 | 0.87 | TSHR (0.70) | TSHRPTPN1SLC5A2CA12CA1 | |
| SCHEMBL15269927 | 0.85 | TSHR (0.61) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL15269929 | 0.85 | TSHR (0.61) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL13082383 | 0.85 | TSHR (0.58) | TSHRPTPN1SLC5A2CA12CA1 | |
| SCHEMBL12425655 | 0.85 | TSHR (0.70) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL12510088 | 0.85 | TSHR (0.70) | TSHRPTPN1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2014-08-28 | — | — | US | disclosed |
| US-7932379-B2 | Methods of producing C-aryl glucoside SGLT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-7375213-B2 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example dapagliflozin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | TSHR 3941/4885PTPN1 1048/4885SLC5A2 1/4885 |
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | TSHR 3941/4885PTPN1 1048/4885SLC5A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.